TOP HEADLINES

Featured Story

  • Glaxo's Ebola vaccine trial set to begin in September

    As the Ebola outbreak continues to claim victims in West Africa, governments and industry alike are racing toward a therapeutic or preventive drug that could help halt its deadly spread and avert future human crises involving the virus.

Advaxis teams up with Merck to test its vaccine in prostate cancer

Just over a month after striking an immunotherapy pact with AstraZeneca, New Jersey biotech Advaxis is back with another Big Pharma agreement. This time, the company will be teaming up with Merck to test its cancer vaccine, ADXS-PSA, in combination with the latter's checkpoint inhibitor pembrolizumab.

Diamyd diabetes vax, once spurned by J&J, gets an EU boost

There's a big patient pool waiting out there for any diabetes vaccine maker that can bring a product to market, but so far, it's been a rocky road. Diamyd Medical is among the companies that have seen their share of setbacks. But after a Phase III stumble back in 2011, the EU is putting forth some cash to test its vaccine in an ongoing combination study.

Mutated poliovirus found to beat vaccine protection

Though polio has been nearly eradicated from the globe, researchers have made a troubling discovery that underscores the need to boost vaccination rates in countries that have seen recent outbreaks as well as develop new, more potent vaccines.

Vaccinogen raises $10M for work on colon cancer vaccine

Frederick, MD-based Vaccinogen has scored $10 million to fund work on its colon cancer candidate, OncoVax.

Pfizer's Prevnar gets $2B boost with CDC nod in older adults

Let the uptake begin. Pfizer has snagged the CDC panel recommendation for Prevnar 13 it's been looking for--a nod for use in adults over the age of 65. And that should result in a sales lift that analysts say could touch $2 billion in peak additional sales potential--for now.

MORE NEWS

From Our Sister Sites

FierceCRO

DPx, the result of a $2.6 billion merger of Patheon and DSM Pharmaceutical Products, has acquired U.S. contract manufacturer Gallus BioPharmaceuticals.

FierceBiotech Research

A gene therapy method tested in mice may eventually be able to replace the current form of treatment for toxin exposures that cause ailments such as botulism.